110 results about "Pbsc mobilization" patented technology

Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and / or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.

Presented are novel instruments intended for use in the diagnosis and treatment of fibrotic soft tissue through soft tissue mobilization therapies performed on, particularly, a human patient. Three such instruments are provided by the invention including a variety of curvilinear and linear tissue-engaging edges and converging surfaces accommodating their use on the irregular contours of numerous soft tissue areas of the human body.

The present invention relates to methods of using granulocyte colony stimulating factor (G-CSF) polypeptide, alone and in conjunction with stromal cell derived factor (SDF-1) polypeptide, to increase the mobilization of c-Kit+ stem cells in the blood, bone marrow, tissue, heart or other organs for the subsequent production of embryoid body-like cell clusters. These embryoid body-like cell clusters can be used for cell replacement therapy, for the treatment of cardiac myopathy and other diseases and disorders, and for screening agents that drive or inhibit differentiation and proliferation.

Methods, cells and compositions of matter are provided for treatment of erectile dysfunction using stem cell therapy. In particular, various stem cells are modified or administered freshly isolated in order to induce smooth muscle regeneration, neural regeneration, and restoration of endothelial function. In some embodiments endogenous stem cells are mobilized or activated to achieve therapeutic benefit. In other embodiments compositions derived from stem cells are utilized for treatment of erectile dysfunction.

The present invention relates to methods for mobilizing hematopoietic facilitating cells (FC) and hematopoietic stem cells (HSC) into a subject's peripheral blood (PB). In particular, the invention relates to the activation of both FLT3 and granulocyte-colony stimulating factor (G-CSF) receptor to increase the numbers of FC and HSC in the PB of a donor. The donor's blood contains both mobilized FC and HSC, and can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient. Therefore, PB containing FC and HSC mobilized by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. Alternatively, the donor's hematopoietic tissue, such as bone marrow, can be treated ex vivo to enrich selectively for FC and HSC populations by activating appropriate cell surface receptors.

The present invention relates to compounds that are capable of modulating CD154 mobilization and that are useful for stabilizing the thrombotic process and reducing the activation of cells involved in an inflammatory response. The present invention also relates to methods useful for identifying such compounds. The present invention also relates to the treatment of platelets for transfusion with metalloproteinase inhibitors to treat or prevent inflammation. The present invention also includes compositions and methods to treat injury and disease related to such biological processes.

Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve inhibition of both Rac1 and Rac2 GTPases to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. The subject's blood can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient and may in the future be utilized to repair a variety of non-hematopoietic tissues. Therefore, hematopoietic stem cells mobilized into a subject's peripheral blood by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. They can also be used for increasing white blood cell survival and for chemotherapy.

A method of obtaining mesenchymal stem cells is provided. The method comprising:(a) administering to a subject an effective amount of a CXCR4 antagonistic peptide as set forth in SEQ ID NO: 1 so as to mobilize the mesenchymal stem cells to peripheral blood of the subject;(b) collecting the mesenchymal stem cells from the peripheral blood; and subsequently or concomitantly(c) purifying the mesenchymal stem cells using a mesenchymal stem cell-specific phenotype.

Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.

The present invention relates to methods and compositions for mobilizing hematopoietic stem cells and / or progenitor cells, and related methods of conditioning for engraftment of transplanted hematopoietic stem cells and / or progenitor cells, and methods of treating diseases requiring hematopoietic stem cell and / or progenitor cell transplantation.

Methods for enhancing the suppressive function of myeloid derived suppressor cells (MDSCs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the small compounds are glatiramer acetate and mitogen activated protein (MAP) kinase inhibitors. In other aspects, these methods include the administration of exogenous MD-SCs or the use of endogenous MDSCs mobilized using stem cell mobilizers. In yet other aspects, compositions containing MDSCs and small compounds of the invention are provided.

The present invention for the first time demonstrated that:(1) bone marrow-derived pluripotent tissue stem cells can be induced in peripheral blood by intravenously administering tissue extract prepared from isolated skin pieces;(2) the substance in the isolated skin pieces, which is responsible for mobilizing bone marrow-derived pluripotent tissue stem cells to peripheral blood, is HMGB1; and(3) HMGB1 with the activity of mobilizing bone marrow-derived pluripotent stem cells to peripheral blood can be easily purified from cultured cells.

The present invention relates to mobilization of stem cells. In particular, the present invention relates to growth factor-induced mobilization of stem cells in vivo for collection or tissue repair.

The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and / or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

A multi-surface instrument for soft tissue mobilization is disclosed, the instrument includes a planar body having a periphery. In a first embodiment, the instrument further includes a hook element, a first round point having a first radius associated therewith, a second round point having a second radius associated therewith, wherein the second radius is larger than the first radius, and a rectangular surface. In a second embodiment, the instrument further includes a plurality of features, each of the plurality of features extends along the periphery of the planar body, wherein each of the features is independently one from the group consisting of: a convex surface, a concave surface, and a linear surface. Methods for using the instrument are also described.

The invention discloses a kit for treating human bone marrow, umbilical cord blood, and peripheral blood cells, and provides a kit for treating human bone marrow, umbilical cord blood, and peripheral blood cells and a cell treatment method which are strong in operationality, high in clinical safety, and convenient for clinical popularization. The kit comprises four reagents: No. A liquid is a diluent; No. B liquid is density fluid; No. C liquid is washing liquid; No. D liquid is erythrocyte-removing liquid. The invention fundamentally solves the problems of high cost, low cell activity, undefined human body influence for markers entering human body, pain for patients due to mobilization agent injection, cumbersome and inapplicable operations, and the like for current cell separation technology.

The invention discloses a process for separating and extracting angelica polysaccharide and application thereof. The process comprises the following steps: directly extracting angelica sinensis crude powder by water, precipitating by using 95% ethanol to obtain crude polysaccharide after concentrating an extracting solution; adding saturated Ca(OH)2 to remove protein after dissolving the crude polysaccharide by water; processing by strong acid cation exchange resin (SACER) and strong-base anion exchange resin (SBAER) respectively; dialyzing by using a dialysis bag after concentrating, so as to obtain the angelica polysaccharide after concentrating. The extraction and separation method disclosed by the invention is simple and feasible, the obtained neutral angelica polysaccharide is high in purity, and the angelica polysaccharide has a significant increasing effect on peripheral blood white blood count (WBC) and LC in mice. Thus, theoretical direction and an experiment basis are provided for further research of the mobilization action of the angelica polysaccharide on hydrogenated soy phosphatidylcholine (HSPC).

The invention provides a preparation for mobilizing mesenchymal stem cells and a method for separating the mesenchymal stem cells. The preparation for mobilizing the mesenchymal stem cells comprises CoCl2, wherein the CoCl2 is a hypoxia mimetic agent, and the dosage is in a range of 5-20mg / kg. The CoCl2 and AMD3100 are used in a combined manner. The dosage of the AMD3100 is 5mg / kg. According to the method for separating the mesenchymal stem cells by using the preparation, the preparation is used for actuating the mesenchymal stem cells to be mobilized, enter peripheral blood and then be separated. The method comprises the following separation steps of: sampling the periphery blood, separating mononuclear cells by using a lymphocyte separating medium, performing resuspension by using a DMEM (dulbeccos modified eagle medium) containing 20% of fetal bovine serum, inoculating to a culture flask, culturing for 7 days, and changing a culture solution, thus obtaining the mesenchymal stem cells of the peripheral blood on the 10th day. The mesenchymal stem cells of the peripheral blood highly express CD90, CD29 and CD44, do not express CD45 and CD34, and have the capacities of in vitro bone formation, fat formation and cartilage differentiation formation. The preparation is high in MSCs (mesenchymal stem cells) mobilization efficiency, and an effective preparation and an effective method are provided for tissue engineering and regenerative medicine.

The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and / or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

Methods to improve hematopoiesis and increase white blood cell counts in subjects and patients using pyrimidine-based inhibitors of Bruton's tyrosine kinase (Btk) are disclosed.

The present invention relates to methods and compositions for mobilizing hematopoietic stem cells and / or progenitor cells, and related methods of conditioning for engraftment of transplanted hematopoietic stem cells and / or progenitor cells, and methods of treating diseases requiring hematopoietic stem cell and / or progenitor cell transplantation.

Methods to improve hematopoiesis and increase white blood cell counts in subjects and patients using pyrimidine-based inhibitors of Bruton's tyrosine kinase (Btk) are disclosed.

The invention relates to a multi-level hole function support material for mobilization endogenous neural stem cell repair spinal cord injuries and a preparation method and application thereof. The preparation method of the material comprises the steps that modified double-bounded chitosan is mixed with a cross-linking agent BIS, 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one anddistilled water to obtain a precursor solution, growth factors are added or not added to prepare a glue precursor solution, the precursor solution is placed into liquid nitrogen for ice crystal guiding,guiding, and then under ultraviolet irradiation at the temperature of subzero 20 DEG C, glue is formed by initiation. The material is provided with guiding holes of different sizes in the inner diameter of the long axis of the material, the space structure needed by neural circuit reconstruction is supplied, endogenous neural stem cells can be directionally migrated to the material transplanting region conveniently to form new born nerve cells, a neural network is formed by multi-level structure growth designed at the nerve synapse edge, the neural circuit at the injured region is rebuilt,and the motor function recovery after spinal cord injuries is promoted.

Compositions of matter, uses, and formulations of food supplements / nutrients capable of eliciting mobilization of various stem / progenitor cells, including hematopoietic stem cells and endothelial progenitor cells are disclosed. In one embodiment a formulation contains a mixture of ellagic acid, vitamin D3, beta 1,3 glucan and a ferment of the bacterium, Lactobacillus fermentum, with an extract of green tea, extract of goji berries, and extract of the root of astragalus added prior to fermentation. Said formulation, originally developed as an antioxidant / immune stimulator was found to have the unexpected property of eliciting stem / progenitor cell mobilization.

The invention relates to a layer-by-layer-self-assembling small-caliber tissue engineering blood vessel and an establishing method thereof. The method mainly comprises the steps that chitosan / beta-cyclodextrin nano slow-release particles are established, and wrapping endothelial progenitor cells are mobilized to capture molecules; natural biological materials or artificial synthetic materials are knitted into artificial blood vessels in an electric spinning method, or decellularization homologous or heterogeneous blood vessels are used; and tissue engineering blood vessel surface modification is carried out, and a layer-by-layer-self-assembling mode is used for modifying molecule nano particles captured and mobilized by wrapping adenosine, receptor stimulant thereof and the like to a biology artificial blood vessel support. The artificial blood vessel can be established conveniently, releasing of medicine can be effectively controlled, medicine sudden releasing can be lowered, and meanwhile good mechanical property and clinic practicability are achieved. Blood vessels of any caliber can be established, and in-vivo induced circulation blood endothelial progenitor cells mobilization and homing can be carried out. Artificial blood vessel endothelialization can be promoted quickly, and meanwhile hemadostenosis and blocking caused by smooth muscle cell pathologic proliferation can be restrained for a long time.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for treating inherited or acquired retinal, choroidal and optic nerve disorders caused by acute or chronic dysregulated reduced ocular blood flow (OBF) and / or energy failure by up regulation of trigemino-vascular system (TVS), trigeminal autonomic brain reflexes (TABRs) and pancreatic trigemino-vagal reflex (TVR) through stimulation of ophthalmic nerve (V1), more specifically but not limited to SP, and CGRP containing unmyelinated C nerve fibers. The invention, in some embodiments thereof, relates to the methods for enhancing SP and CGRP expression in neurovascular tissue of the retina and choroid. The invention, in some embodiments thereof, relates to SP / CGRP mediated pathways, including those involved in vasodilatation, augmentation of OBF, RPE proliferation, prevention of apoptosis, suppressing neuroinflammation, promoting migration and differentiation of vascular endothelial cells as well as mobilization of endogenous mesenchymal stem cells (EMSCs) from the bone marrow to the circulation to accelerate tissue repair. The site of stimulation of V1 nerve includes but not limited to; nasal vestibule nasal bridge, forehead, and upper eyelids. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated by sympatholytic agents specifically antioxidants. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for retinal, choroidal and / or optic nerve disorders. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in ophthalmic artery and its branches by the release of Vasoactive intestinal peptide (VIP),substance P and CGRP thereof increasing OBF to the retina, choroid and optic nerve in subject's with acute or chronic dysregulated, reduced OBF. The invention, in some embodiments thereof, is also related to the methods for improving delivery of oxygen, glucose, vitamin A, humoral mediators, growth factors, stem cells and pharmacological agents to the targeted tissues of the retina, choroid and optic nerve. The invention, in some embodiments thereof, relates to the methods for improving pancreatic insulin secretion, thereof to enhance glucose uptake by PRs and other retinal cells. Additionally or alternatively, the invention relates to restoration of transduction of signaling in cone PRs by ONS induced glutamate release. The methods of the invention, in some embodiments thereof, include priming of the retina choroid and optic nerve thereof to enhance the efficacy of cell transplantation therapy. The methods of the invention, in some embodiments thereof, also include identifying a subject prone to or suffering from a disease or condition associated with reduced OBF. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment where the patients are at pre-clinical stage of the disease. The OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.The present invention, in some embodiments thereof, relates to a method and / or device for treatment of dysregulated reduced blood (e.g. reduced ocular blood flow) and, more particularly, but not exclusively, to methods and / or devices for treatment retinal, choroidal and optic nerve disorders. Optionally, treatment may include application of an effective amount of ONS ophthalmic nerve stimulation alone and / or in combination with pen-ocular administration of substance Neuropeptides / Platelet Rich Plasma (N / PRP) and / or ascorbic acid as a sympatholytic agent

The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and / or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit significant activity in mobilization of bone, making them therapeutic agents for the treatment or prophylaxis of osteoporosis, osteomalacia, osteopenia, renal osteodystrophy and hypoparathyroidism.

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three- stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizingfactors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example,from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL-2.